EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSCSEG00000002322
Gene Symbol: LOC103384656
3 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSCSEG00000020305
Gene Symbol: KCNQ2
4 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSCSEG00000006974
Gene Symbol: KCNQ3
1 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSCSEG00000000525
Gene Symbol: KCNQ5
1 Cross references
200 Possible Orthologues:

Presenilin-1-Like

Ensembl ID : ENSCSEG00000009722
Gene Symbol: LOC103381643
3 Cross references
202 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSCSEG00000012374
Gene Symbol: LOC103393526
3 Cross references
403 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSCSEG00000000127
Gene Symbol: LOC103382849
3 Cross references
257 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSCSEG00000006795
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Progesterone Receptor-Like

Ensembl ID : ENSCSEG00000015724
Gene Symbol: LOC103391230
2 Cross references
205 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSCSEG00000010959
Gene Symbol: PTGDR2
3 Cross references
145 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSCSEG00000013302
Gene Symbol: PTGDR2
4 Cross references
134 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSCSEG00000013665
Gene Symbol: PTGER2
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).